NSHIFT
27.8.2021 12:10:11 CEST | Business Wire | Press release
nShift (www.nshift.com ), global provider of cloud delivery management solutions for e-commerce shops, retailers, manufacturers and 3PL companies, announces its launch.
With over 100+ pre-built third-party integrations into e-commerce and other shippers’ most critical IT systems and an unmatched carrier library delivering connectivity into over 700+ carriers, nShift offers customers an end-to-end cloud platform to automate and optimize the entire delivery management process – from label creation to delivery tracking and last mile logistics to returns management. nShift’s solutions have successfully enabled almost 1 billion annual shipments globally for e-commerce shops, retailers, manufacturers and 3PL companies. Through its extensive carrier library, nShift has unparalleled shipping visibility and reach, unlocking significant scalability for its customers – from 1 to millions of shipments annually – across the globe.
“I am extremely honored and excited to be joining nShift at such a pivotal time in its growth,” said Lars Pedersen, who was recently appointed CEO of nShift. “While our name is changing, we are more committed than ever to continuing to provide the vital connectivity in delivery management, visibility, and efficiency for which our 90,000+ customers rely on us. We are thrilled to announce our new brand together with our latest e-commerce innovations, nShift Checkout and nShift Return (formerly known as Returnado). Our platform enables customers to worry less and ship smarter with up to 10-20% higher e-commerce-shop conversions, 60% fewer delivery related support calls, and 30% increase in repurchase rates on returned products.”
Through the acquisition of Returnado, a Stockholm-based e-commerce returns management provider, nShift adds critical technology to its cloud delivery management platform with a streamlined return process for shippers, carriers, and recipients. Returnado’s returns expertise spans marquee brands such as Helly Hansen and Asket and demonstrates its significant capabilities to serve a very complicated portion of the logistics value chain.
Marlin Equity Partners and Francisco Partners, two of the world's leading technology investors, will remain the majority stakeholders in nShift.
Peter Chung, a Managing Director at Marlin Equity Partners, said, “We are excited to continue delivering against the nShift mission of enabling our customers to worry less and ship smarter via the Company’s collective scale and breadth of its consolidated, end-to-end cloud delivery management platform. Today, e-commerce and other shippers have a singular platform from which they can eliminate geographical barriers to growth and drive supply chain efficiency and visibility all while improving the overall delivery experience for constituents across the logistics value chain.”
Petri Oksanen, a Partner at Francisco Partners, added, “This is an exciting step forward and the beginning of the next chapter of transformational growth for nShift. With the recent acquisition and integration of Returnado, we are in a position now more than ever to continue to deliver the very best solutions for our customers and help them solve first-to-last mile logistics challenges, deliver tangible cost savings, and drive innovation in our industry.”
About nShift (www.nshift.com )
Established in 2021, nShift is the global leading provider of cloud delivery management solutions enabling the frictionless shipment and return of almost 1 billion shipments across 190 countries. nShift’s software is used globally by e-commerce, retail, manufacturing and 3PL shippers. The company is headquartered in London and Oslo. It has over 450 employees across offices in Sweden, Finland, Norway, Denmark, United Kingdom, Poland, the Netherlands, Belgium, Romania and Switzerland.
Stakeholders
About Marlin Equity Partners (www.marlinequity.com )
Marlin Equity Partners is a global investment firm with over $7 billion of capital under management. The firm is focused on providing corporate parents, shareholders and other stakeholders with tailored solutions that meet their business and liquidity needs. Marlin invests in businesses across multiple industries where its capital base, industry relationships and extensive network of operational resources significantly strengthen a company’s outlook and enhance value. Since its inception, Marlin, through its group of funds and related companies, has successfully completed over 170 acquisitions. The firm is headquartered in Los Angeles, California with an additional office in London.
About Francisco Partners (www.franciscopartners.com )
Francisco Partners is a leading global investment firm that specializes in partnering with technology and technology-enabled businesses. Since its launch over 20 years ago, Francisco Partners has invested in more than 300 technology companies, making it one of the most active and longstanding investors in the technology industry. With more than $25 billion in assets under management, the firm invests in opportunities where its deep sectoral knowledge and operational expertise can help companies realize their full potential.
Companies Which Have Merged to Form nShift (note - all now rebranded as part of nShift with immediate effect)
About Returnado
Returnado is a Swedish e-commerce returns management platform launched in 2016. Returnado’s solutions optimize the “reverse e-commerce” returns process for retailers and consumers, and provides real-time analytics enabling customers to achieve 30%+ repurchase rates.
About Unifaun
Unifaun provides innovative delivery management solutions to carriers, shippers, and parcel recipients across the European transportation ecosystem. With an extensive partner ecosystem and carrier library, Unifaun enables customers to efficiently deliver almost 300 million shipments annually. Unifaun has over 200 employees across Sweden, Finland, Norway, Denmark, the Netherlands, Belgium, Germany, and Poland.
About Consignor
Consignor supports customers across the delivery processes by making it simpler, quicker, and cost-effective to ship orders to customers and by making delivery a competitive advantage. Consignor provides delivery management solutions, enabled through a wide-ranging carrier library, connecting shippers’ websites and warehouses with their customers. Consignor has more than 170 employees across offices in Oslo, Stockholm, Helsinki, Copenhagen, Aarhus, Bucharest, and London.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210827005148/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom